Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | THRA | P10827 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3763749 | 0.87 | TDP1 (0.47) | TDP1PLA2G1BATG4BFKBP1ASMN1; SMN2 | |
| SCHEMBL3765148 | 0.83 | TDP1 (0.38) | TDP1PLA2G1BATG4BFKBP1ASMN1; SMN2 | |
| SCHEMBL27821001 | 0.75 | TDP1 (0.44) | TDP1PLA2G1BATG4BFKBP1ASMN1; SMN2 | |
| SCHEMBL7237387 | 0.74 | TRPA1 (0.42) | TDP1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2071123 | 0.73 | TSHR (0.46) | TDP1SMN1; SMN2KMT2AMEN1NPSR1 | |
| SCHEMBL3480424 | 0.71 | TDP1 (0.37) | TDP1SMN1; SMN2KMT2AMEN1KDM4E | |
| SCHEMBL3757635 | 0.70 | POLB (0.35) | FKBP1AKMT2AMEN1KDM4EL3MBTL1 | |
| SCHEMBL29183237 | 0.69 | SMN1; SMN2 (0.41) | TDP1SMN1; SMN2KMT2AMEN1L3MBTL1 | |
| SCHEMBL27349891 | 0.69 | TDP1 (0.47) | TDP1PLA2G1BATG4BSMN1; SMN2KMT2A | |
| SCHEMBL12883131 | 0.69 | TDP1 (0.48) | TDP1PLA2G1BATG4BFKBP1ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045390-B2 | Haloalkylmethyleneoxyphenyl-substituted ketoenols | BAYER CROPSCIENCE AG (DE) | 2015-06-02 | — | — | US | disclosed |
| US-20140213813-A9 | Haloalkylmethyleneoxyphenyl-Substituted Ketoenols | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-31 | — | — | US | disclosed |
| US-20140031577-A1 | Haloalkylmethyleneoxyphenyl-Substituted Ketoenols | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| US-8518985-B2 | Haloalkylmethyleneoxyphenyl-substituted ketoenols | BAYER CROPSCIENCE AG (DE) | 2013-08-27 | — | — | US | disclosed |
| US-20100311593-A1 | Haloalkylmethyleneoxyphenyl-substituted ketoenols | BAYER CROPSCIENCE AG (DE) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213813-A9 | Haloalkylmethyleneoxyphenyl-Substituted Ketoenols | PHYKPL, KCNE1, CSNK1E | TDP1 3861/4885PLA2G1B 996/4885ATG4B 1861/4885 |
| US-20140031577-A1 | Haloalkylmethyleneoxyphenyl-Substituted Ketoenols | PHYKPL, KCNE1, CSNK1E | TDP1 3861/4885PLA2G1B 996/4885ATG4B 1861/4885 |
| US-20100311593-A1 | Haloalkylmethyleneoxyphenyl-substituted ketoenols | PHYKPL, KCNE1, CSNK1E | TDP1 3861/4885PLA2G1B 996/4885ATG4B 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.